Clinical Trial

Preoperative Planning With PSMA-PET in Melanoma Surgery Trial

Study acronym: PPPIMS
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 1, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a non-randomised, single-centre Phase 2 study, investigating whether the diagnostic biomarker, prostate-specific membrane antigen (PSMA), can detect melanoma metastases using PSMA PET/ CT.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-08-15; most recent amendment 2025-06-26.
Status change: Not Yet Recruiting → Recruiting 2025-06-26
Trial Details
NCT Number NCT06560905
Lead Sponsor Royal Marsden NHS Foundation Trust
Conditions Malignant Melanoma
Enrollment 16 participants
Start Date 2025-03-11
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-01